1
|
Zhylka A, Sollmann N, Kofler F, Radwan A, De Luca A, Gempt J, Wiestler B, Menze B, Schroeder A, Zimmer C, Kirschke JS, Sunaert S, Leemans A, Krieg SM, Pluim J. Reconstruction of the Corticospinal Tract in Patients with Motor-Eloquent High-Grade Gliomas Using Multilevel Fiber Tractography Combined with Functional Motor Cortex Mapping. AJNR Am J Neuroradiol 2023; 44:283-290. [PMID: 36797033 PMCID: PMC10187805 DOI: 10.3174/ajnr.a7793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Accepted: 01/17/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND AND PURPOSE Tractography of the corticospinal tract is paramount to presurgical planning and guidance of intraoperative resection in patients with motor-eloquent gliomas. It is well-known that DTI-based tractography as the most frequently used technique has relevant shortcomings, particularly for resolving complex fiber architecture. The purpose of this study was to evaluate multilevel fiber tractography combined with functional motor cortex mapping in comparison with conventional deterministic tractography algorithms. MATERIALS AND METHODS Thirty-one patients (mean age, 61.5 [SD, 12.2] years) with motor-eloquent high-grade gliomas underwent MR imaging with DWI (TR/TE = 5000/78 ms, voxel size = 2 × 2 × 2 mm3, 1 volume at b = 0 s/mm2, 32 volumes at b = 1000 s/mm2). DTI, constrained spherical deconvolution, and multilevel fiber tractography-based reconstruction of the corticospinal tract within the tumor-affected hemispheres were performed. The functional motor cortex was enclosed by navigated transcranial magnetic stimulation motor mapping before tumor resection and used for seeding. A range of angular deviation and fractional anisotropy thresholds (for DTI) was tested. RESULTS For all investigated thresholds, multilevel fiber tractography achieved the highest mean coverage of the motor maps (eg, angular threshold = 60°; multilevel/constrained spherical deconvolution/DTI, 25% anisotropy threshold = 71.8%, 22.6%, and 11.7%) and the most extensive corticospinal tract reconstructions (eg, angular threshold = 60°; multilevel/constrained spherical deconvolution/DTI, 25% anisotropy threshold = 26,485 mm3, 6308 mm3, and 4270 mm3). CONCLUSIONS Multilevel fiber tractography may improve the coverage of the motor cortex by corticospinal tract fibers compared with conventional deterministic algorithms. Thus, it could provide a more detailed and complete visualization of corticospinal tract architecture, particularly by visualizing fiber trajectories with acute angles that might be of high relevance in patients with gliomas and distorted anatomy.
Collapse
Affiliation(s)
- A Zhylka
- From the Department of Biomedical Engineering (A.Z., J.P.), Eindhoven University of Technology, Eindhoven, The Netherlands
| | - N Sollmann
- Department of Diagnostic and Interventional Radiology (N.S.), University Hospital Ulm, Ulm, Germany
- Department of Diagnostic and Interventional Neuroradiology (N.S., F.K., B.W., C.Z., J.S.K.), School of Medicine, Klinikum rechts der Isar
- TUM-Neuroimaging Center (N.S., C.Z., J.S.K., S.M.K.), Klinikum rechts der Isar
- Department of Radiology and Biomedical Imaging (N.S.), University of California, San Francisco, San Francisco, California
| | - F Kofler
- Helmholtz AI (F.K.), Helmholtz Zentrum Munich, Munich, Germany
- Department of Diagnostic and Interventional Neuroradiology (N.S., F.K., B.W., C.Z., J.S.K.), School of Medicine, Klinikum rechts der Isar
- Image-Based Biomedical Modeling (F.K., B.M.)
- Department of Informatics, TranslaTUM (F.K., B.W.), Central Institute for Translational Cancer Research
| | - A Radwan
- Department of Imaging and Pathology (A.R., S.S.), Translational MRI
- Department of Neurosciences (A.R., S.S.), Leuven Brain Institute, Katholieke Universiteit Leuven, Leuven, Belgium
| | - A De Luca
- Image Sciences Institute (A.D.L., A.L.)
- Neurology Department (A.D.L.), University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - J Gempt
- Department of Neurosurgery (J.G., A.S., S.M.K.), School of Medicine, Klinikumrechts der Isar, Technical University of Munich, Munich, Germany
| | - B Wiestler
- Department of Diagnostic and Interventional Neuroradiology (N.S., F.K., B.W., C.Z., J.S.K.), School of Medicine, Klinikum rechts der Isar
- Department of Informatics, TranslaTUM (F.K., B.W.), Central Institute for Translational Cancer Research
| | - B Menze
- Image-Based Biomedical Modeling (F.K., B.M.)
- Department of Quantitative Biomedicine (B.M.), University of Zurich, Zurich, Switzerland
| | - A Schroeder
- Department of Neurosurgery (J.G., A.S., S.M.K.), School of Medicine, Klinikumrechts der Isar, Technical University of Munich, Munich, Germany
| | - C Zimmer
- Department of Diagnostic and Interventional Neuroradiology (N.S., F.K., B.W., C.Z., J.S.K.), School of Medicine, Klinikum rechts der Isar
- TUM-Neuroimaging Center (N.S., C.Z., J.S.K., S.M.K.), Klinikum rechts der Isar
| | - J S Kirschke
- Department of Diagnostic and Interventional Neuroradiology (N.S., F.K., B.W., C.Z., J.S.K.), School of Medicine, Klinikum rechts der Isar
- TUM-Neuroimaging Center (N.S., C.Z., J.S.K., S.M.K.), Klinikum rechts der Isar
| | - S Sunaert
- Department of Imaging and Pathology (A.R., S.S.), Translational MRI
- Department of Neurosciences (A.R., S.S.), Leuven Brain Institute, Katholieke Universiteit Leuven, Leuven, Belgium
| | - A Leemans
- Image Sciences Institute (A.D.L., A.L.)
| | - S M Krieg
- TUM-Neuroimaging Center (N.S., C.Z., J.S.K., S.M.K.), Klinikum rechts der Isar
- Department of Neurosurgery (J.G., A.S., S.M.K.), School of Medicine, Klinikumrechts der Isar, Technical University of Munich, Munich, Germany
| | - J Pluim
- From the Department of Biomedical Engineering (A.Z., J.P.), Eindhoven University of Technology, Eindhoven, The Netherlands
| |
Collapse
|
2
|
Hong SW, Kim SH, Lim SH, Lee EJ, Kim SH, Ku CR, Kim EH. Clinical Relevance of New World Health Organization Classification System for Pituitary Adenomas: A Validation Study With 2-Year Experience. Front Oncol 2021; 11:739290. [PMID: 34589436 PMCID: PMC8476031 DOI: 10.3389/fonc.2021.739290] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 08/23/2021] [Indexed: 12/28/2022] Open
Abstract
Background The new World Health Organization (WHO) classification system proposed a cell lineage-based classification scheme for pituitary adenomas in which transcription factors (TFs) play a major role as key classifiers. We aimed to evaluate clinical relevance of the new classification system in a clinical setting. Methods TF staining was retrospectively performed for 153 clinically and histologically well characterized pituitary adenomas. Then, 484 pituitary adenomas were prospectively stained for TFs and then for relevant pituitary hormones. TF and hormone stain-based diagnoses were compared, and differences in clinical manifestations were evaluated. Results The accuracies of antibodies for three TFs were successfully validated and had an overall matching rate was 89.6%. We identified 50 (10.4%) cases with discrepancies between TF and pituitary hormone stains. Gonadotroph adenomas lacking follicle-stimulating hormone and luteinizing hormone stains account for most discrepancies. Null cell adenomas may be more prevalent than reported and may be clinically more aggressive than gonadotroph adenomas. Conclusion The new WHO classification is mostly well matched with the traditional classification. However, until the new classification is further validated and interpreted in the context of long-term clinical outcomes, routine histological examination should include full slate of immunostains for pituitary hormones as well as TFs.
Collapse
Affiliation(s)
- Seung Woo Hong
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea
| | - Se Hoon Kim
- Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.,Pituitary Tumor Center, Severance Hospital, Seoul, South Korea
| | - Seung Hoon Lim
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea
| | - Eun Jig Lee
- Pituitary Tumor Center, Severance Hospital, Seoul, South Korea.,Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, South Korea.,Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
| | - Sun Ho Kim
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea.,Department of Neurosurgery, Ewha Woman's University College of Medicine, Seoul, South Korea
| | - Cheol Ryong Ku
- Pituitary Tumor Center, Severance Hospital, Seoul, South Korea.,Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, South Korea.,Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
| | - Eui Hyun Kim
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea.,Pituitary Tumor Center, Severance Hospital, Seoul, South Korea.,Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, South Korea
| |
Collapse
|